Document is current
Any future updates will be listed below
-
Authors
Sherpa, Mingma G.
Sinha, Sutapa https://orcid.org/0000-0002-7274-9622
Han, Weiguo https://orcid.org/0000-0003-4842-4833
Darby, Heather C.
Parikh, Sameer A. https://orcid.org/0000-0002-3221-7314
Kay, Neil E. https://orcid.org/0000-0002-5951-5055
Wang, Zhiquan https://orcid.org/0000-0002-8243-7251
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA233332)
Michael W. and Georgia Taylor Michelson
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA251801)
- License Information
-
More Information
Article History
Received: 27 October 2025
Revised: 6 February 2026
Accepted: 10 March 2026
First Online: 20 March 2026
Competing interests
: NEK: Advisory Board for: AbbVie, AstraZeneca, BeOne, Janssen, Pharmacyclics. DSMC (Data Safety Monitoring Committee) for: AstraZeneca, BMS-Celgene, Dren Bio. Research funding from: AbbVie, Acerta Pharma, AstraZeneca, Genentech, Pharmacyclics/Jannsen, Merck. All funds are directed to the Mayo Clinic and are not retained personally. SAP: Research funding has been provided to the institution from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which Sameer A. Parikh is a principal investigator. Honoraria have been provided to the institution by Pharmacyclics, Merck, AstraZeneca, Janssen, Beone, Genentech, Amgen, MingSight Pharmaceuticals, TG Therapeutics, Novalgen Limited, Kite Pharma, and AbbVie for Sameer A. Parikh’s participation in consulting activities/advisory board meetings and DSMC meetings.
